Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial Progress
November 22, 2024 04:49 ET
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Claudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering. ...
Global Clinical Trials Connect Conference 2025: Collaboration, Innovation and Enhancing Quality in Clinical Trials (London, United Kingdom - May 28-29, 2025)
November 21, 2024 10:25 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Global Clinical Trials Connect 2025" conference has been added to ResearchAndMarkets.com's offering. The Global Clinical Trials Connect 2025 will...
Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
November 21, 2024 08:00 ET
|
Science 37, Inc.
Science 37 contributes almost half (47%) of the U.S. enrollment for GSK Phase 3 rare disease study while bolstering participant retention figures.
SPR® Therapeutics Debuts New SPRINT® PNS Data for Low Back, Shoulder, Knee, and Headache at the 23rd Annual ASRA Pain Medicine Meeting
November 21, 2024 08:00 ET
|
SPR Therapeutics, Inc.
SPR Therapeutics announced eight scientific abstracts that will be presented at the upcoming ASRA Pain Medicine Meeting
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
November 19, 2024 03:30 ET
|
Curium
ST. LOUIS, Mo., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that it has completed enrollment of its Phase 3 SOLAR-RECUR clinical trial. The trial is a...
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 15, 2024 07:29 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with...
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 14, 2024 16:10 ET
|
Fortress Biotech, Inc.
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
November 14, 2024 14:31 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
November 14, 2024 09:20 ET
|
PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
November 11, 2024 12:43 ET
|
AdipoPharma
STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug,...